

Product datasheet

Anti-Filamin A (phospho S2152) antibody ab51229

1 References 1 Image

Overview

<b>Product name</b>	Anti-Filamin A (phospho S2152) antibody
<b>Description</b>	Rabbit polyclonal to Filamin A (phospho S2152)
<b>Host species</b>	Rabbit
<b>Specificity</b>	ab51229 detects endogenous levels of Filamin A only when phosphorylated at serine 2152.
<b>Tested applications</b>	<b>Suitable for:</b> WB
<b>Species reactivity</b>	<b>Reacts with:</b> Human <b>Predicted to work with:</b> Mouse, Rat 
<b>Immunogen</b>	A synthetic phospho-peptide derived from human Filamin A around the phosphoicrylation site of serine 2152 (A-P-S <sup>P</sup> -V-A).
<b>Positive control</b>	Extracts from 293 cells treated with EGF (200ng/ml, 5min)
<b>General notes</b>	<p>The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.</p> <p>If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&amp;As</p>

Properties

<b>Form</b>	Liquid
<b>Storage instructions</b>	Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
<b>Storage buffer</b>	<p>pH: 7.40</p> <p>Preservative: 0.02% Sodium azide</p> <p>Constituents: 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride, PBS</p> <p>Without Mg+2 and Ca+2</p>
<b>Purity</b>	Immunogen affinity purified
<b>Purification notes</b>	ab51229 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.

**Clonality** Polyclonal

**Isotype** IgG

## Applications

**The Abpromise guarantee** Our [Abpromise guarantee](#) covers the use of ab51229 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
WB		1/300 - 1/1000. Predicted molecular weight: 281 kDa.

## Target

**Function** Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNA may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking.

**Tissue specificity** Ubiquitous.

**Involvement in disease** Defects in FLNA are the cause of periventricular nodular heterotopia type 1 (PVNH1) [MIM:300049]; also called nodular heterotopia, bilateral periventricular (NHBP or BPNH). PVNH is a developmental disorder characterized by the presence of periventricular nodules of cerebral gray matter, resulting from a failure of neurons to migrate normally from the lateral ventricular proliferative zone, where they are formed, to the cerebral cortex. PVNH1 is an X-linked dominant form. Heterozygous females have normal intelligence but suffer from seizures and various manifestations outside the central nervous system, especially related to the vascular system. Hemizygous affected males die in the prenatal or perinatal period.

Defects in FLNA are the cause of periventricular nodular heterotopia type 4 (PVNH4) [MIM:300537]; also known as periventricular heterotopia Ehlers-Danlos variant. PVNH4 is characterized by nodular brain heterotopia, joint hypermobility and development of aortic dilation in early adulthood.

Defects in FLNA are the cause of otopalatodigital syndrome type 1 (OPD1) [MIM:311300]. OPD1 is an X-linked dominant multiple congenital anomalies disease mainly characterized by a generalized skeletal dysplasia, mild mental retardation, hearing loss, cleft palate, and typical facial anomalies. OPD1 belongs to a group of X-linked skeletal dysplasias known as oto-palato-digital syndrome spectrum disorders that also include OPD2, Melnick-Needles syndrome (MNS), and frontometaphyseal dysplasia (FMD). Remodeling of the cytoskeleton is central to the modulation of cell shape and migration. FLNA is a widely expressed protein that regulates re-organization of the actin cytoskeleton by interacting with integrins, transmembrane receptor complexes and second messengers. Males with OPD1 have cleft palate, malformations of the ossicles causing deafness and milder bone and limb defects than those associated with OPD2. Obligate female carriers of mutations causing both OPD1 and OPD2 have variable (often milder) expression of a similar phenotypic spectrum.

Defects in FLNA are the cause of otopalatodigital syndrome type 2 (OPD2) [MIM:304120]; also known as cranioorodigital syndrome. OPD2 is a congenital bone disorder that is characterized by abnormally modeled, bowed bones, small or absent first digits and, more variably, cleft palate, posterior fossa brain anomalies, omphalocele and cardiac defects.

Defects in FLNA are the cause of frontometaphyseal dysplasia (FMD) [MIM:305620]. FMD is a congenital bone disease characterized by supraorbital hyperostosis, deafness and digital anomalies.

Defects in FLNA are the cause of Melnick-Needles syndrome (MNS) [MIM:309350]. MNS is a severe congenital bone disorder characterized by typical facies (exophthalmos, full cheeks, micrognathia and malalignment of teeth), flaring of the metaphyses of long bones, s-like curvature of bones of legs, irregular constrictions in the ribs, and sclerosis of base of skull.

Defects in FLNA are the cause of X-linked congenital idiopathic intestinal pseudoobstruction (CIIPX) [MIM:300048]. CIIPX is characterized by a severe abnormality of gastrointestinal motility due to primary qualitative defects of enteric ganglia and nerve fibers. Affected individuals manifest recurrent signs of intestinal obstruction in the absence of any mechanical lesion.

Defects in FLNA are the cause of FG syndrome type 2 (FGS2) [MIM:300321]. FG syndrome (FGS) is an X-linked disorder characterized by mental retardation, relative macrocephaly, hypotonia and constipation.

Defects in FLNA are the cause of terminal osseous dysplasia (TOD) [MIM:300244]. A rare X-linked dominant male-lethal disease characterized by skeletal dysplasia of the limbs, pigmentary defects of the skin and recurrent digital fibroma during infancy. A significant phenotypic variability is observed in affected females.

Defects in FLNA are the cause of cardiac valvular dysplasia X-linked (CVDX) [MIM:314400]. A rare X-linked heart disease characterized by mitral and/or aortic valve regurgitation. The histologic features include fragmentation of collagenous bundles within the valve fibrosa and accumulation of proteoglycans, which produces excessive valve tissue leading to billowing of the valve leaflets.

#### **Sequence similarities**

Belongs to the filamin family.  
Contains 1 actin-binding domain.  
Contains 2 CH (calponin-homology) domains.  
Contains 24 filamin repeats.

#### **Domain**

Comprised of a NH2-terminal actin-binding domain, 24 internally homologous repeats and two hinge regions. Repeat 24 and the second hinge domain are important for dimer formation.

#### **Post-translational modifications**

Phosphorylated upon DNA damage, probably by ATM or ATR (By similarity). Phosphorylation extent changes in response to cell activation.  
The N-terminus is blocked.


#### **Cellular localization**

Cytoplasm > cell cortex. Cytoplasm > cytoskeleton.

---

#### **Images**

---



Western blot - Anti-Filamin A (phospho S2152) antibody (ab51229)

**All lanes :** Anti-Filamin A (phospho S2152) antibody (ab51229) at 1/300 dilution

**Lane 1 :** 293 cell lysate stimulated with EGF (200ng/ml, 5min) with immunizing (blocking) peptide

**Lane 2 :** 293 cell lysate stimulated with EGF (200ng/ml, 5min)

**Predicted band size:** 281 kDa

**Please note:** All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

### Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

### Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors